COVID-19 Resurgence in 2025: Omicron NB.1.8.1 Drives Surge with Enhanced Immune Escape

Figure 1. SARS-CoV-2 virus structure

SARS-CoV-2, a member of the Coronaviridae family, is an enveloped, single-stranded positive-sense RNA virus (+ssRNA). Its particles are nearly spherical or ellipsoidal, with a diameter of 60–140 nm, featuring distinctive “crown-like” spike proteins on the surface. Below are its core components:

1. Lipid Bilayer Envelope: The outermost layer, derived from the host cell membrane, is lipid-rich and protects the virus’s internal structure. It embeds three key transmembrane proteins: Spike (S), Envelope (E), and Membrane (M) proteins.
2. Spike Protein (S Protein): Critical for infection, shaped like a mushroom, consisting of S1 and S2 subunits. S1 binds to the human ACE2 receptor, while S2 mediates viral and cellular membrane fusion. Mutations in the S protein of the NB.1.8.1 variant enhance immune escape, enabling it to partially bypass vaccine or prior infection immunity, a key factor in the current resurgence.
3. Envelope Protein (E Protein): A small transmembrane protein involved in virus assembly and release. It plays a supportive role in the viral life cycle, regulating ion channel activity that may affect virus release efficiency.
4. Nucleocapsid Protein (N Protein): Binds viral RNA to form the nucleocapsid complex, protecting the genome and aiding in viral replication and transcription.
5. Membrane Protein (M Protein): The most abundant envelope protein, responsible for the virus particle’s shape and structural stability. It interacts with S, E, and N proteins to ensure smooth viral assembly, acting as the virus’s structural “scaffold.”

The ongoing evolution of SARS-CoV-2 has led to the emergence ofmultiple variants, driven by mutations in its genome, particularly in the spike protein. These variantsclassified as Variants of Concern (VOCs) or Variants of Interest (VOls) by organizations such as theWorld Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).exhibit changes that can impact transmissibility, disease severity, immune escape, or theeffectiveness of diagnostics and therapeutics. The current resurgence in China, driven by theOmicron NB.1.8.1 subvariant, underscores the virus's ability to adapt and evade immunity. Keyvariants include:
       - Alpha (B.1.1.7): First identified in the United Kingdom in late 2020, this variant showed increasedtransmissibility due to mutations like N501Y in the spike protein, which enhanced binding affinityto the human ACE2 receptor.

       - Beta (B.1.351): Detected in South Africa, it carried mutations such as E484K, which reducedneutralization by antibodies from prior infections or vaccines, contributing to immune escape.

       - Delta (B.1.617.2): Originating in lndia, this highly transmissible variant caused severe disease,driven by mutations like L452R and T478K in the spike protein, which improved viral fitness and
partially evaded immunity.

       - Omicron (B.1.1.529): ldentified in late 2021, Omicron and its sublineages (e.g., BA.1, BA.2.NB.1.8.1) are characterized by numerous mutations in the spike protein, particularly in thereceptor-binding domain (RBD). The NB.1.8.1 subvariant, dominant in the current Chineseoutbreak, harbors additional mutations that enhance its ability to evade immunity from vaccinesor prior infections. This has led to increased outpatient and inpatient positivity rates, particularlyin southern provinces, despite generally mild symptoms.Emerging Sublineages: Ongoing genomic surveillance continues to track new Omicron-derivedsubvariants, which may further impact transmissibility or immune escape. These variants arisedue to the high mutation rate of RNA viruses, fueled by replication errors and selective pressuresfrom population immunity.

Continuous global monitoring and genomic sequencing are essential to detect and characterizenew variants, guiding updates to vaccines, therapeutics, and public health measures to mitigateresurgences like the one currently observed in China.

abinScience specializes in developing and producing high-quality, innovative biological reagents and technical solutions for global researchers. abinScience drives product innovation and service optimization. It offers an extensive library of virus-related proteins and antibodies with high precision and broad applicability, providing essential tools for cutting-edge research in virology, immunology, and life sciences.